The Added Value of Bevacizumab Concomitantly Administered with Carboplatin versus Carboplatin Alone in Patients with Recurrent Glioblastomas

Kaloshi, Gentian; Diamandi, P.; Cakani, Bujar; Brace, Gramoz; Rroji, Arben; Petrela, Mentor

doi:10.5301/tj.5000210

Cited by 5 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional agents used against GBM include other nitrosoureas such as fotemustine, which can be administered as a single agent or in combination with PCV (P: procarbazine, C: lomustine and V: vincristine). Carboplatin, etoposide and irinotecan are other regimens that have shown modest efficacy after single or combined administration [ 37 ]. Clinical trials with cediranib, gefitinib and erlotinib for recurrent GBM have not shown an improvement in prolonging survival so far [ 38 , 39 , 40 ].…”

Section: Newly Diagnosed and Recurrent Gbm: Treatment And Managementmentioning

confidence: 99%

Advances in Brain Tumor Surgery for Glioblastoma in Adults

et al. 2017

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common primary intracranial neoplasia, and is characterized by its extremely poor prognosis. Despite maximum surgery, chemotherapy, and radiation, the histological heterogeneity of GBM makes total eradication impossible, due to residual cancer cells invading the parenchyma, which is not otherwise seen in radiographic images. Even with gross total resection, the heterogeneity and the dormant nature of brain tumor initiating cells allow for therapeutic evasion, contributing to its recurrence and malignant progression, and severely impacting survival. Visual delimitation of the tumor’s margins with common surgical techniques is a challenge faced by many surgeons. In an attempt to achieve optimal safe resection, advances in approaches allowing intraoperative analysis of cancer and non-cancer tissue have been developed and applied in humans resulting in improved outcomes. In addition, functional paradigms based on stimulation techniques to map the brain’s electrical activity have optimized glioma resection in eloquent areas such as the Broca’s, Wernike’s and perirolandic areas. In this review, we will elaborate on the current standard therapy for newly diagnosed and recurrent glioblastoma with a focus on surgical approaches. We will describe current technologies used for glioma resection, such as awake craniotomy, fluorescence guided surgery, laser interstitial thermal therapy and intraoperative mass spectrometry. Additionally, we will describe a newly developed tool that has shown promising results in preclinical experiments for brain cancer: optical coherence tomography.

show abstract

Section: Newly Diagnosed and Recurrent Gbm: Treatment And Managementmentioning

confidence: 99%

Advances in Brain Tumor Surgery for Glioblastoma in Adults

et al. 2017

View full text Add to dashboard Cite

show abstract

Treatment options for progression or recurrence of glioblastoma: a network meta-analysis

McBain

Lawrie

Rogozińska

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundGlioblastoma (GBM) is a highly malignant brain tumour that almost inevitably progresses or recurs a er first line standard of care. There is no consensus regarding the best treatment/s to o er people upon disease progression or recurrence. For the purposes of this review, progression and recurrence are considered as one entity. ObjectivesTo evaluate the e ectiveness of further treatment/s for first and subsequent progression or recurrence of glioblastoma (GBM) among people who have received the standard of care (Stupp protocol) for primary treatment of the disease; and to prepare a brief economic commentary on the available evidence.

show abstract